期刊文献+

新型腺病毒载体的制备及其特性研究 被引量:3

Generation and characterization of fibre modified adenovirus vectors
下载PDF
导出
摘要 目的:本研究在普通腺病毒载体(Adv)纤毛头节区插入了具有整合素特异性的RGD肽,制备了一种新型RGD-Adv,以克服Adv基因转导的柯萨奇腺病毒受体依赖性。方法:用体外连接法构建RGD-Adv,并考察其基因转效率、稳定性及体外、体内毒性。结果:RGD-Adv可有效地实现向受试细胞转导基因,其转导能力随病毒量的增加而加强。结论:具有av亲和性的RGD-Adv是一种安全高效的新型腺病毒载体,将在基因治疗及实验研究中发挥重要作用。 Objective: In the present study, We developed and assess an integrin-targeted fiber-mutant Ad vector containing the ArgGly-Asp (RGD) peptide motif on the fiber knob for the transfection of melanoma cell lines. Methods: We constructed RGD-Adv by in vitro ligation method, and investigated the efficiency of gene transdution in melanoma cells, studied its stability, in vitro,and in vivo toxicology. Results: For in vivo and in vitro,gene transfer the RGD-Adv more efficient than the vector containing wild type fiber via an CARindependent cell entry pathway. Conclusion: These results revealed that gene delivery by RGD-Adv was more efficient than that byconventional Adv and suggest that a-integrin-targeted Adv will be of great utility for gene therapy and gene transfer experiments.
出处 《重庆医科大学学报》 CAS CSCD 2006年第3期330-333,共4页 Journal of Chongqing Medical University
关键词 腺病毒载体 RGD肽 整合素 Adenovirus vector RGD peptid Integrin
  • 相关文献

参考文献13

  • 1Baum BJ,Goldsmith CM,Kok MR,et al.Advances in vector-mediated gene transfer[J].Immunol Lett,2003;90(2-3):145-149.
  • 2Cao H,Koehler DR,Hu J.Adenoviral vectors for gene replacement therapy[J].Viral Immunol,2004;17(3):327-333.
  • 3St George JA.Gene therapy progress and prospects:adenoviral vectors[J].Gene Ther,2003;10(14):1135-1141.
  • 4Green NK,Seymour LW.Adenoviral vectors:systemic delivery and tumor targeting[J].Cancer Gene Ther,2002;9(12):1036-1042.
  • 5Barnett BG,Crews CJ,Douglas JT.Targeted adenoviral vectors[J].Biochim Biophys Acta,2002;1575(1-3):1-14.
  • 6Mizuguchi H,Kay MA,Hayakawa T.In vitro ligation-based cloning of foreign DNAs into the E3 and El deletion regions for generation of recombinant adenovirus vectors[J].Biotechniques,2001;30(5):1112-1114,1116.
  • 7Mizuguchi H,Kay MA,Hayakawa T.Approaches for generating recombinant adenovirus vectors[J].Adv Drug Deliv Rev,2001; 52(3):165-176.
  • 8Worgall S,Wolff G,Falck-Pedersen E,et al.Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration[J].Hum Gene Ther,1997;8(1):37-44.
  • 9Alemany R,Suzuki K,Curiel DT.Blood clearance rates of adenovirus type 5 in mice[J].J Gen Virol,2000;81(Pt 11):2605-2609.
  • 10Calderwood DA.Integrin activation[J].J Cell Sci,2004;117(Pt 5):657-666.

同被引文献54

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部